Development of cocrystals through crystal engineering is a viable strategy to formulate poorly water-soluble active pharmaceutical ingredients as stable crystalline solid forms with enhanced bioavailability. This study presents a controlled cocrystallization process by cooling for the 1:1 cocrystal of Ketoconazole, an antifungal class II drug with the Fumaric acid coformer. This was successfully set up following the meta-stable zone width determination in acetone–water 4:6 (V/V) and pure ethanol. Considering the optimal crystallization data, laboratory scale-up processes were carried out at 1 g batch size, efficiently delivering the cocrystal in high yields up to 90% pure and single phase as revealed by powder X-ray diffraction. Biological assays in vitro showed improved viability and oxidative damage of the cocrystal over Ketoconazole on human dermal fibroblasts and hepatocarcinoma cells; in vivo, on Wistar rats, the cocrystal increased oral Ketoconazole bioavailability with transient minor biochemical transaminases increases and without histological liver alterations. Locally on Balb C mice, it induced no epicutaneuous sensitization. A molecular docking study conducted on sterol 14α-demethylase (CYP51) enzyme from the pathogenic yeast Candida albicans revealed that the cocrystal interacts more efficiently with the enzyme compared to Ketoconazole, indicating that the coformer enhances the binding affinity of the active ingredient.
1 June 2017 in Materials Science and Engineering: C
Objective: This research aimed to investigate the compatibility of the Ketoconazole-Adipic Acid (KTZ-AA) co-crystal, which exhibits an improved dissolution profile over pure Ketoconazole, with various solid pharmaceutical excipients, as well as its in silico antifungal potential. Methods: Binary physical mixtures (1:1 w/w) of KTZ-AA co-crystal and excipients were analyzed using differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier-transform infrared spectroscopy (FT-IR), and powder X-ray diffraction (PXRD). The molecular docking study targeting the sterol 14α-demethylase (CYP51) enzyme of the pathogenic yeast Candida albicans was performed. Results: DSC results indicated compatibility between co-crystal and six tested excipients: lactose monohydrate, polyvinylpyrrolidone K90, microcrystalline cellulose, corn starch, colloidal silicon dioxide, and talc. In the case of the co-crystal and magnesium stearate mixture, DSC revealed a change in the thermal behavior, suggesting the formation of a eutectic system. However, TGA demonstrated that the decomposition profile of the co-crystal remained unaffected in all binary mixtures. PXRD and FT-IR further confirmed the absence of chemical interactions between the co-crystal and all excipients under ambient conditions. Moreover, the KTZ-AA co-crystal maintained its chemical stability without degradation after three months storage under accelerated conditions (40°C/75% RH). The molecular docking study demonstrated that co-crystallization of KTZ with AA enhances its binding affinity to CYP51 enzyme compared to KTZ alone. Conclusion: The excipient compatibility study conducted on the Ketoconazole-Adipic Acid co-crystal confirmed its potential for development as a solid oral dosage form with improved antifungal activity, presenting a promising alternative to the parent drug.
25 March 2022 in Acta Crystallographica Section C Structural Chemistry